Welcome back to the Psychedelic Invest week in review. Here are the stories that moved the psychedelic sector during the week of October 20–26, 2025 — from clinical readouts to regulatory shifts and the capital flowing through the space.
atai Life Sciences N.V. (ATAI): atai closes $149.5 million public offering
atai completed its public offering, selling 27,283,750 common shares (including full exercise of the underwriters' option) for aggregate gross proceeds of roughly $149.5 million. Management said proceeds, together with existing cash, will fund clinical development across its pipeline. The closing capped a financing that added several new specialist healthcare investors to the register.
Source: theglobeandmail.com
Silo Pharma, Inc. (SILO): Silo Pharma updates SPC-15 PTSD program and adds digital-asset treasury strategy
Silo Pharma provided a corporate update on its lead candidate SPC-15, an intranasal treatment for PTSD and anxiety, saying it is preparing an IND application to the FDA after positive safety study results and continued work on its delivery system. Separately, the company launched a digital-asset treasury strategy, disclosing initial cryptocurrency purchases. The dual announcement mixed clinical progress with an unconventional balance-sheet move.
Source: quiverquant.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.